Jenny E. Murase
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jenny E. Murase has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
Misha M. Heller
Department of Dermatology, Emory University, Atlanta, Georgia
9 shared publicationsCollin M. Blattner
Des Moines University, Des Moines, IA, USA
7 shared publicationsDedee F. Murrell
St George Hospital, Sydney, Australia; The George Institute of Global Health, Sydney, Australia
7 shared publicationsEmi M. Murase
Integrative Skin Research, Sacramento, California; Department of Biological Sciences, University of California, Davis, Davis, California
7 shared publicationsJodie Raffi
From the, *Department of Dermatology, University of California, San Francisco
7 shared publicationsMelissa Danesh
University of California San Francisco
7 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (9) , 4749-4760
Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
- 11 August 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (9) , 4749-4760
Open AccessSkin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
- 7 April 2026
- Published by Elsevier in Clinics in Dermatology
- Vol. 44 (3) , 387-392
Vitamins and related substances in skin health: Use and restrictions in pregnancy
- 7 April 2026
- Published by Elsevier in Clinics in Dermatology
- Vol. 44 (3) , 387-392
Vitamins and related substances in skin health: Use and restrictions in pregnancy
- Open Access
- 30 October 2025
- Published by European Medical Group in EMJ Dermatology
- Vol. 13 (1) , 104-113
Safe Medical Management of Atopic Dermatitis in Pregnancy and Lactation
Atopic dermatitis (AD) is a common and chronic skin condition that can be significantly impacted by the physiological and immunological...
- 30 October 2025
- Published by European Medical Group in EMJ Dermatology
- Vol. 13 (1) , 104-113
Open AccessSafe Medical Management of Atopic Dermatitis in Pregnancy and Lactation
Atopic dermatitis (AD) is a common and chronic skin condition that can be significantly impacted by the physiological and immunological...
- 30 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (3) , 936-940
International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes
- 30 October 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (3) , 936-940
International multicenter case series of gestational dupilumab exposure in the treatment of atopic dermatitis: Maternal complications and fetal outcomes
- Open Access
- 8 September 2025
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 11 (3) , e220
Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?
Objective: To assess the safety of tumor necrosis factor inhibitors (TNFi) during pregnancy, specifically in relation to infant infection rates, vaccine efficacy, and vaccine-associated adverse events in infants exposed to TNFi in utero and through breast milk. Data Sources: A comprehensive literature review was conducted using PubMed and Google Scholar. The review included retrospective studies, prospective studies, and systematic reviews published until June 2024, focusing on TNFi exposure during pregnancy and breastfeeding. Study Selections: Studies reporting on infant infection rates, vaccination outcomes, and adverse events following in-utero or breastfeeding exposure to TNFi agents, including certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. Narrative reviews were excluded, while systematic reviews were considered. Results: The review indicates that gestational exposure to TNFi does not increase the risk of severe infections in infants. Additionally, no significant rise in infections was found in infants exposed to TNFi through breast milk. Vaccination outcomes, including efficacy and adverse events, were comparable between exposed and unexposed infants. However, caution is advised when administering the Bacille Calmette–Guerin vaccine to infants exposed to TNFi, particularly within the first year of life. Conclusion: TNFi appear to be safe during pregnancy and breastfeeding. The data indicate that TNFi does not increase the risk of severe infections or vaccine complications in infants, with the exception of the Bacille Calmette–Guerin vaccine, for which a more cautious approach is recommended. These findings reinforce the use of TNFi in women with inflammatory conditions who are pregnant or breastfeeding, providing benefits to both maternal and fetal health.
- 8 September 2025
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 11 (3) , e220
Open AccessAnalysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?
Objective: To assess the safety of tumor necrosis factor inhibitors (TNFi) during pregnancy, specifically in relation to infant infection rates, vaccine efficacy, and vaccine-associated adverse events in infants exposed to TNFi in utero and through breast milk. Data Sources: A comprehensive literature review was conducted using PubMed and Google Scholar. The review included retrospective studies, prospective studies, and systematic reviews published until June 2024, focusing on TNFi exposure during pregnancy and breastfeeding. Study Selections: Studies reporting on infant infection rates, vaccination outcomes, and adverse events following in-utero or breastfeeding exposure to TNFi agents, including certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. Narrative reviews were excluded, while systematic reviews were considered. Results: The review indicates that gestational exposure to TNFi does not increase the risk of severe infections in infants. Additionally, no significant rise in infections was found in infants exposed to TNFi through breast milk. Vaccination outcomes, including efficacy and adverse events, were comparable between exposed and unexposed infants. However, caution is advised when administering the Bacille Calmette–Guerin vaccine to infants exposed to TNFi, particularly within the first year of life. Conclusion: TNFi appear to be safe during pregnancy and breastfeeding. The data indicate that TNFi does not increase the risk of severe infections or vaccine complications in infants, with the exception of the Bacille Calmette–Guerin vaccine, for which a more cautious approach is recommended. These findings reinforce the use of TNFi in women with inflammatory conditions who are pregnant or breastfeeding, providing benefits to both maternal and fetal health.
- 22 March 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 93 (2) , 466-468
Rapid clinical response to nemolizumab in dermatologic diseases associated with pruritus and burning: A multicenter case series
- 22 March 2025
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 93 (2) , 466-468
Rapid clinical response to nemolizumab in dermatologic diseases associated with pruritus and burning: A multicenter case series
- 7 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , e113-e114
To patch or not to patch on dupilumab: That is the question
- 7 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , e113-e114
To patch or not to patch on dupilumab: That is the question
- Open Access
- 10 October 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (11) , 3175-3181
Regulated Medical Waste Reduction in the Dermatology Clinic
Introduction The disposal of regulated medical waste (RMW) in the healthcare setting can be both costly and environmentally harmful. Prior studies have found large amounts of waste disposed of in RMW containers are inappropriately placed. Few studies to date have investigated the efficacy of waste reduction practices in the dermatology setting. Methods This study aims to evaluate the effectiveness of a practice-wide intervention in reducing RMW in the outpatient dermatology setting. By performing daily waste audits and two concurrent educational interventions, the amount of RMW produced and percent of appropriately placed RMW will be measured. Further analysis will occur by comparing pre-intervention values to post-intervention values. Results The percentage of waste properly placed in RMW containers prior to any intervention was 11%. Following both educational interventions, the percentage of waste properly placed in RMW containers increased by 56.1% (CI 43.7–68.5%) and the percentage of total waste produced that was identified and disposed of as RMW decreased by 6.0% (95% CI 1.2–10.8%). Conclusion Our study provides practical data for dermatology providers to make small changes which can result in significant reductions of regulated medical waste, potentially providing benefits to the environment and cost-savings.
- 10 October 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (11) , 3175-3181
Open AccessRegulated Medical Waste Reduction in the Dermatology Clinic
Introduction The disposal of regulated medical waste (RMW) in the healthcare setting can be both costly and environmentally harmful. Prior studies have found large amounts of waste disposed of in RMW containers are inappropriately placed. Few studies to date have investigated the efficacy of waste reduction practices in the dermatology setting. Methods This study aims to evaluate the effectiveness of a practice-wide intervention in reducing RMW in the outpatient dermatology setting. By performing daily waste audits and two concurrent educational interventions, the amount of RMW produced and percent of appropriately placed RMW will be measured. Further analysis will occur by comparing pre-intervention values to post-intervention values. Results The percentage of waste properly placed in RMW containers prior to any intervention was 11%. Following both educational interventions, the percentage of waste properly placed in RMW containers increased by 56.1% (CI 43.7–68.5%) and the percentage of total waste produced that was identified and disposed of as RMW decreased by 6.0% (95% CI 1.2–10.8%). Conclusion Our study provides practical data for dermatology providers to make small changes which can result in significant reductions of regulated medical waste, potentially providing benefits to the environment and cost-savings.
- Open Access
- 26 March 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (4) , 853-859
Virtual Learning Decreases the Carbon Footprint of Medical Education
Introduction The environmental impact of holding in-person academic conferences and continuing medical education (CME) programs can be significant. In-person conferences provide a unique social and professional platform to engage in networking and foster professional development; however, there is an opportunity for hybrid and virtual platforms to provide CME for broader audiences looking to improve their clinical skills and strengthen their knowledge base. This study seeks to describe the reduction in carbon emissions associated with a webinar hosted by an online dermatology-focused medical education platform. Methods This cross-sectional study used the location of deidentified virtual attendees of a webinar to predict the carbon emissions produced if attendees had instead traveled to the location of the most recent Integrative Dermatology Symposium (Sacramento, CA). Following collection of each virtual attendee’s location, the mode of transportation was predicted on the basis of each participant’s distance to the conference. Results The estimated carbon emissions were calculated for 576 participants. The total estimated, unadjusted carbon emissions for both attendees predicted to fly or drive was 370,100 kg CO2. The emissions produced per participant from those expected to fly to an in-person CME after adjusting for all additional passengers on every flight were 4.5 kg CO2. The emissions produced per participant from those expected to drive were 42.7 kg CO2. Conclusion The use of a virtual CME webinar led to a significant reduction in travel-related carbon dioxide emissions when compared to running the same program in-person event. When accounting for all passengers traveling via plane on any flight, driving to an event produced more emissions per participant than flying.
- 26 March 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (4) , 853-859
Open AccessVirtual Learning Decreases the Carbon Footprint of Medical Education
Introduction The environmental impact of holding in-person academic conferences and continuing medical education (CME) programs can be significant. In-person conferences provide a unique social and professional platform to engage in networking and foster professional development; however, there is an opportunity for hybrid and virtual platforms to provide CME for broader audiences looking to improve their clinical skills and strengthen their knowledge base. This study seeks to describe the reduction in carbon emissions associated with a webinar hosted by an online dermatology-focused medical education platform. Methods This cross-sectional study used the location of deidentified virtual attendees of a webinar to predict the carbon emissions produced if attendees had instead traveled to the location of the most recent Integrative Dermatology Symposium (Sacramento, CA). Following collection of each virtual attendee’s location, the mode of transportation was predicted on the basis of each participant’s distance to the conference. Results The estimated carbon emissions were calculated for 576 participants. The total estimated, unadjusted carbon emissions for both attendees predicted to fly or drive was 370,100 kg CO2. The emissions produced per participant from those expected to fly to an in-person CME after adjusting for all additional passengers on every flight were 4.5 kg CO2. The emissions produced per participant from those expected to drive were 42.7 kg CO2. Conclusion The use of a virtual CME webinar led to a significant reduction in travel-related carbon dioxide emissions when compared to running the same program in-person event. When accounting for all passengers traveling via plane on any flight, driving to an event produced more emissions per participant than flying.
- 7 March 2024
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (3) , 465-471
Management of Acne in Pregnancy
Acne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin, metronidazole, benzoyl peroxide, salicylic acid, dapsone, and retinoids, were reviewed. Systemic treatments, such as zinc supplements, cephalexin, cefadroxil, amoxicillin, azithromycin, erythromycin, and corticosteroids, typically second-line for acne, were also reviewed. Alternative treatments such as light therapy and cosmetic procedures were also evaluated. Due to recommendation of sunscreen utilization during acne treatments, sunscreen usage during pregnancy was also assessed. Management of acne during unplanned pregnancy was discussed in further detail regarding safety and adverse effects. Through summarized tables and examples of studies demonstrating safety and efficacy of treatments, the following is a resource for providers and patients to utilize for management of acne during pregnancy.
- 7 March 2024
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 25 (3) , 465-471
Management of Acne in Pregnancy
Acne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin, metronidazole, benzoyl peroxide, salicylic acid, dapsone, and retinoids, were reviewed. Systemic treatments, such as zinc supplements, cephalexin, cefadroxil, amoxicillin, azithromycin, erythromycin, and corticosteroids, typically second-line for acne, were also reviewed. Alternative treatments such as light therapy and cosmetic procedures were also evaluated. Due to recommendation of sunscreen utilization during acne treatments, sunscreen usage during pregnancy was also assessed. Management of acne during unplanned pregnancy was discussed in further detail regarding safety and adverse effects. Through summarized tables and examples of studies demonstrating safety and efficacy of treatments, the following is a resource for providers and patients to utilize for management of acne during pregnancy.